Frontlight ResearchEarly access
Not yet taking people in SpainPhase 4
Compares two heart medicines, levosimendan and dobutamine, in people with weak heart pumping
Compares levosimendan and dobutamine in adults with heart failure and reduced heart pumping.
Key facts
- Who runs it
- Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol
- Where
- Badalona, SpainSee the site
- Registry title
- LEVOMEMS: Comparison of the effects of dobutamine and levosimendan in the current treatment of heart diseases.
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 10 people, planned
- Started
- 14 Feb 2023
- Planned end
- 31 Jul 2025
- Type of study
- Interventional
- Record updated
- 3 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure and a weak pumping heart. It compares how dobutamine and levosimendan change lung artery pressure and the amount of blood the heart pumps.
- Age
- Over 18 years
- Sex
- All
- Disease stage
- Heart failure with a left ventricular ejection fraction (FEVI) under 35% on an echocardiogram in the last 6 months. NYHA class above III, with limited function despite optimized heart failure and diuretic treatment. A hospital stay or decompensation treated as an outpatient with a diuretic in the last six months, which led to the CardioMEMS device.
- Earlier treatment
- Optimized heart failure treatment and a diuretic, as above.
Main reasons for not taking part
- Creatinine clearance under 20 ml / min
- Systolic blood pressure under 90 mmHg
- Women who can have children without effective contraception, or who are breastfeeding
- Pregnancy
- Hypersensitivity to the active ingredients or any excipient
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age> 18 years
- FEVI <35% for echocardiography in the last 6 months
- Functional class NYHA> III with functional impairment despite optimized treatment of HF and diuretic with admission or decompensation treated on an outpatient basis with diuretic in the last six months that motivate the implementation of the CardioMEMS device
- Signing of informed consent
Who cannot take part
- Hypersensitivity to the active ingredients or to any of the excipients
- Creatinine clearance <20 ml / min
- Presión arterial sistólica <90 mmHg
- Pregnant or fertile women (who are in the period between menorrhagia and menopause) without effective contraceptive coverage, or in breastfeeding
Where in Spain
- Hospital Germans Trias i PujolBadalona, SpainNot yet recruiting
About the trial
What the trial wants to find out
To assess the change in the pulmonary arterial pressure and the cardiac output with levosimendan or dobutamine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- LEVOMEMS: Comparison of the Hemodynamic Profile of Dobutamine and Levosimendan in the Current Therapeutic Context
- Plain-language title
- Compares two heart medicines, levosimendan and dobutamine, in people with weak heart pumpingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 3 December 2024